Literature DB >> 23449805

Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.

Jianmin Zuo1, Andrew D Hislop, Carol S Leung, Shereen Sabbah, Martin Rowe.   

Abstract

Evasion of immune T cell responses is crucial for persistent viruses to establish a normal carrier state. Most studies on active immune modulation mechanisms have focused on the stage of virus production in infected cells, when large numbers of viral antigens and potential immune modulators are expressed. For oncogenic viruses such as Kaposi's sarcoma-associated herpesvirus (KSHV), which is carried as a lifelong infection, usually with little harmful effect, but can cause various tumors, the immune evasion strategies can also be relevant in the context of tumorigenesis. Here we report that the virus-encoded interferon regulatory factor 3 (vIRF3) latent viral gene expressed in KSHV-related tumors functions as a potent immunevasin. Expression of vIRF3 downregulates surface major histocompatibility complex class II (MHC-II) DR expression with slow kinetics but, more importantly, can substantially inhibit recognition by KSHV-specific CD4 T cells prior to its effects on MHC-II DR downregulation in model cell systems. This property of vIRF3 is only partly due to its ability to inhibit the transcription of CIITA and, thus, MHC-II expression; CIITA-independent inhibition of MHC-II transcripts and another as yet unidentified posttranscriptional mechanism are also involved in qualitatively modulating the availability of specific peptide/MHC-II complexes at the cell surface. Consistent with these observations, the vIRF3-expressing KSHV-associated primary effusion lymphoma (PEL) lines are generally resistant to recognition by KSHV-specific CD4 T cells. Interestingly, some PEL lines exhibit small subpopulations with lower vIRF3 expression that can be recognized. These data implicate vIRF3 as a critical determinant of the MHC-II antigen presentation function in KSHV-associated PELs that is likely to be important in the pathogenesis of these tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449805      PMCID: PMC3648188          DOI: 10.1128/JVI.00250-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.

Authors:  L M Butler; H C Jeffery; R L Wheat; H M Long; P C Rae; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression.

Authors:  Young C Shin; Chul-Hyun Joo; Michaela U Gack; Hye-Ra Lee; Jae U Jung
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

3.  Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.

Authors:  Dan Li; Lu Qian; Changguo Chen; Ming Shi; Ming Yu; Meiru Hu; Lun Song; Beifen Shen; Ning Guo
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

4.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression.

Authors:  Katharina Schmidt; Effi Wies; Frank Neipel
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

5.  Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily.

Authors:  Emanuele Amodio; James J Goedert; Patrizia Barozzi; Giovanni Riva; Alberto Firenze; Filippa Bonura; Enza Viviano; Nino Romano; Mario Luppi
Journal:  Cancer Sci       Date:  2011-07-28       Impact factor: 6.716

6.  Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.

Authors:  O Flore; S Rafii; S Ely; J J O'Leary; E M Hyjek; E Cesarman
Journal:  Nature       Date:  1998-08-06       Impact factor: 49.962

7.  The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function.

Authors:  Jianmin Zuo; Wendy Thomas; Daphne van Leeuwen; Jaap M Middeldorp; Emmanuel J H J Wiertz; Maaike E Ressing; Martin Rowe
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

8.  The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5.

Authors:  Effi Wies; Alexander S Hahn; Katharina Schmidt; Cornelia Viebahn; Nadine Rohland; Anja Lux; Tim Schellhorn; Angela Holzer; Jae U Jung; Frank Neipel
Journal:  J Biol Chem       Date:  2009-01-07       Impact factor: 5.157

9.  T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells.

Authors:  Shereen Sabbah; Ya Jankey Jagne; Jianmin Zuo; Thushan de Silva; Mohammad M Ahasan; Christian Brander; Sarah Rowland-Jones; Katie L Flanagan; Andrew D Hislop
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

Review 10.  Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway.

Authors:  Jianmin Zuo; Martin Rowe
Journal:  Viruses       Date:  2012-08-22       Impact factor: 5.048

View more
  12 in total

1.  Identification of collaboration patterns of dysfunctional pathways in breast cancer.

Authors:  Xinyong Zhu; Lianyuan Tao; Jing Yao; Pengjun Sun; Lijuan Pei; Jiye Li; Zhihua Long; Ye Wang; Fengliang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.

Authors:  Suhani Thakker; Pravinkumar Purushothaman; Namrata Gupta; Shanthan Challa; Qiliang Cai; Subhash C Verma
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

3.  Molecular Biology of KSHV in Relation to HIV/AIDS-Associated Oncogenesis.

Authors:  Meilan He; Fan Cheng; Suzane Ramos da Silva; Brandon Tan; Océane Sorel; Marion Gruffaz; Tingting Li; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2019

Review 4.  How do viruses trick B cells into becoming lymphomas?

Authors:  Ethel Cesarman
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

Review 5.  KSHV: pathways to tumorigenesis and persistent infection.

Authors:  Louise Giffin; Blossom Damania
Journal:  Adv Virus Res       Date:  2014       Impact factor: 9.937

6.  The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.

Authors:  Laura L Quinn; Luke R Williams; Claire White; Calum Forrest; Jianmin Zuo; Martin Rowe
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

7.  IRF-4-mediated CIITA transcription is blocked by KSHV encoded LANA to inhibit MHC II presentation.

Authors:  Qiliang Cai; Shuvomoy Banerjee; Amanda Cervini; Jie Lu; Andrew D Hislop; Richard Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

8.  Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function.

Authors:  Samantha J Williamson; Samantha M Nicol; Michael Stürzl; Shereen Sabbah; Andrew D Hislop
Journal:  PLoS Pathog       Date:  2016-11-28       Impact factor: 6.823

Review 9.  The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.

Authors:  Jorge Alfonso León Machado; Viktor Steimle
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

Review 10.  Regulation of the Macroautophagic Machinery, Cellular Differentiation, and Immune Responses by Human Oncogenic γ-Herpesviruses.

Authors:  Christian Münz
Journal:  Viruses       Date:  2021-05-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.